Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study investigated the efficacy and safety of insulin degludec (IDeg) once daily (OD), varying injection timing day to day in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: This 26-week, open-label, treat-to-target, noninferiority trial compared IDeg forced flexible (Forced-Flex) OD (given in a fixed schedule with a minimum 8 and maximum 40 hours between doses) with IDeg or insulin glargine (IGlar) given at the same time daily OD. In the 26-week extension, all IDeg subjects were transferred to a free-flexible (Free-Flex) regimen, which allowed any-time-of-day dosing, and compared with subjects continued on IGlar. RESULTS: After 26 treatment weeks, mean glycosylated hemoglobin was reduced with IDeg Forced- Flex (-0.40%), IDeg (-0.41%), and IGlar (-0.58%). IDeg Forced-Flex noninferiority was achieved. Fasting plasma glucose reductions were similar with IDeg Forced-Flex and IGlar but greater with IDeg (-2.54 mmol/L) than IDeg Forced-Flex (-1.28 mmol/L) (P = .021). At week 52, IDeg Free-Flex subjects had similar glycosylated hemoglobin but greater fasting plasma glucose reductions than IGlar subjects (-1.07 mmol/L) (P = .005). Confirmed hypoglycemia rates (plasma glucose <3.1 mmol/L or severe hypoglycemia) were similar at weeks 26 and 52. Nocturnal confirmed hypoglycemia was lower with IDeg Forced-Flex vs IDeg (37%; P = .003) and IGlar (40%; P = .001) at week 26 and 25% lower with IDeg Free-Flex vs IGlar (P = .026) at week 52. CONCLUSIONS: IDeg can be administered OD at any time of day, with injection timing varied without compromising glycemic control or safety vs same-time-daily IDeg or IGlar. This may improve basal insulin adherence by allowing injection-time adjustment according to individual needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a result of the treat-to-target design, a comparison can be made in terms of differences in endpoints such as hypoglycaemia (but not, for example, HbA1c), as illustrated in Table 4 [48–54].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All of the phase III trials with IDeg were designed as treat-to-target trials striving for an ambitious (fasting) blood glucose level target of 4–5 mmol/L (70–90 mg/dL).”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the studies showed that there was no apparent association between the development of cross-reacting antibodies and hypoglycaemia, HbA1c or insulin dose [48, 49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The studies found that, even with such extreme dosing windows, glycaemic control and safety with IDeg were not compromised in comparison to the subjects receiving IDeg or IGlar once daily always at the same time of day [49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“two treat-to-target, randomised studies where extreme dosing intervals of 8–40 h were used in subjects with T1DM and T2DM over a treatment duration of 26–52 weeks [49, 53].”
From A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance (2014) · cites this paper as [49]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 1×
“fected by perceived burden of therapy (1, 6).”
BackgroundMire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624 · cited 1×
“Antibody analyses were performed at Celerion Switzerland AG (Fehraltorf, Switzerland), using a validated RIA method (14, 15).”
MethodSection XXIV. Partition Chromatographs
(2009) · Biotechnology · doi:10.1201/9781420084498-31 · Cited by 590
Research works printed but not linked: 5
- Anderson, 2003, Self-reported compliance with insulin injection therapy in subjects with type 1 and type 2 diabetes, Diabetes Metab, 29, A275
- Jonassen, 2010, Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation, Diabetes, 59, A11
- Heise, 2011, Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine, Diabetes, 60, LB11
- Lantus, 2007, Lantus package insert
- Heise, 2011, The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state, Diabetes, 60, A263
Cited by
Items 101–200 of 218
Garg, S. K., Selam, J. L., Bhargava, A., Schloot, N. C., Luo, J., Zhang, Q., Jacobson, J. G., & Hoogwerf, B. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12740 · Cited by 11
“Variable dosing intervals have also been examined with insulin degludec in patients with T1D.24 The degludec study did not have a lead-in period, so patients were switched directly from their prestudy insulin to variable-time dosed degludec (8-40 hours), fixed-time dosed degludec (24 hours) or fixed-time dosed glargin…”
BackgroundInfluentialFulcher, G., Mehta, R., Fita, E. G., Ekelund, M., & Bain, S. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0531-0 · Cited by 12
Self-citationLalic, N. M., Russel-Szymczyk, M., Culic, M., Tikkanen, C. K., & Chubb, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0426-0 · Cited by 13
New Insulins and Insulin Therapy
Danne, T., & Bolinder, J. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.1505 · Cited by 11
Predieri, B., Suprani, T., Maltoni, G., Graziani, V., Bruzzi, P., Zucchini, S., & Iughetti, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00462 · Cited by 13
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · Diabetes Care · doi:10.2337/dci25-0015 · Cited by 19
Takahashi, H., Nishimura, R., Onda, Y., Ando, K., Tsujino, D., & Utsunomiya, K. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1293652 · Cited by 9
Advances in Care for Insulin-Requiring Patients Without Closed Loop
Lal, R., Buckingham, B. A., & Maahs, D. M. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0084 · Cited by 10
Martín, Zhou, Y., Takagi, T., & Tian, Y. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01410-x · Cited by 11
Are newer insulin analogues better for people with Type 1 diabetes?
Misra, S., & Mathieu, C. (2018) · Diabetic Medicine · doi:10.1111/dme.13891 · Cited by 14
Self-citationAn Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Wu, P., Liu, Z., Jiang, X., & Fang, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191031104653 · Cited by 9
Gilor, C., Culp, W. T. N., Ghandi, S., Silva, J. A. D. C. E. E., Ladhar, A., & Hulsebosch, S. E. (2019) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2019.04.001 · Cited by 9
Schmitt, J. A., & Scott, M. L. (2019) · Hormone Research in Paediatrics · doi:10.1159/000504707 · Cited by 9
Insulin degludec is a new ultra-long-acting insulin analogue
Dedov, I. I., & Shestakova, M. V. (2014) · Diabetes Mellitus · doi:10.14341/dm2014291-104 · Cited by 8
Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons
Hanif, N., Wu, H., Xu, P., Li, Y., Bibi, A., Zulfiqar, A., Iqbal, M. Z., Tahir, M., Zhang, X., & Ali, A. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44020059 · Cited by 7
“Anyhow, it was declared that treatment with Degludec showed identical [93,95] or lesser throughout hypoglycemic events and lesser or rare night-time hypoglycemic events [91,92,94,95] in comparison with the Gla-100.”
ResultIkushima, I., Kaku, K., Hirao, K., Bardtrum, L., & Haahr, H. L. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12399 · Cited by 9
Cohen, C. M., Thorsted, B. L., Wolden, M. L., Chodick, G., & Karasik, A. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0297-9 · Cited by 9
Lane, W. S., Weatherall, J., Gundgaard, J., & Pollock, R. F. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1384383 · Cited by 8
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00722-y · Cited by 8
Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update
Pedersen‐Bjergaard, U., Fabricius, T. W., & Thorsteinsson, B. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1970136 · Cited by 8
A primer on concentrated insulins: what an internist should know
Barnosky, A., Shah, L., Meah, F. A., Emanuele, N., Emanuele, M. A., & Mazhari, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1159909 · Cited by 8
Preumont, V., & Buysschaert, M. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.04.007 · Cited by 8
Drenthen, L. C. A., Ajie, M., Abbink, E. J., Rodwell, L., Thijssen, D. H. J., Tack, C. J., & de Galan, B. E. (2023) · Diabetologia · doi:10.1007/s00125-023-05893-9 · Cited by 8
Saboo, B., Chandalia, H. B., Ghosh, S. K., Kesavadev, J., Kochar, I. S., Prasannakumar, K. M., Sarda, A., Bantwal, G., Mehrotra, R., & Rai, M. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230310150905 · Cited by 7
“The BEGIN Basal Bolus Type 1 and BEGIN Flex-T1 trials showed comparable FPG reductions and response rates in terms of achieving the HbA1c target of 7% between both Gla-100 and IDeg-100 [34, 36].”
BackgroundMethodResultMedium-Term Effects of Insulin Degludec on Patients with Type 1 Diabetes Mellitus
Nakae, R., Kusunoki, Y., Katsuno, T., Tokuda, M., Akagami, T., Murai, K., Hamaguchi, T., Miyagawa, J., & Namba, M. (2014) · Drugs in R&D · doi:10.1007/s40268-014-0048-6 · Cited by 7
Vora, J. P., Seufert, J., Solberg, H., Kinduryte, O., Johansen, T., & Hollander, P. A. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12621 · Cited by 8
“0 [0 to 76] 3770: BEGIN Flex T1 (26 weeks) [11] Once daily 164 12.”
Self-citationPremix insulins in type 1 diabetes: the coming of degludec/aspart
Rendell, M. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1585427 · Cited by 7
“insulin shots for as long as 40 h fromone day to the next [53].”
BackgroundRuddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
Brunton, S., Kruger, D. F., & Funnell, M. M. (2016) · Clinical Diabetes · doi:10.2337/diaclin.34.1.34 · Cited by 8
“dec allows for f lexible timing of day-to-day dosing, and flexible dosing (at intervals of 8–40 hours) results in glycemic control and overall and nocturnal hypoglycemia rates similar to those resulting from fixed dosing (44,45,51).”
BackgroundNishimura, A., Harashima, S., Fukushige, H., Wang, Y., Liu, Y., Hosoda, K., & Inagaki, N. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0238-7 · Cited by 9
Fadini, G. P., Buzzetti, R., Nicolucci, A., Larosa, M., Rossi, M. C., Cucinotta, D., On behalf of the RESTORE-2 Study Group, Gabellieri, E., Alberto, M., Pagotto, U., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01925-9 · Cited by 7
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
Kaku, K., Wolden, M. L., Hyllested-Winge, J. L., & Nørtoft, E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0225-z · Cited by 6
Lualdi, C., Silverii, G. A., Dicembrini, I., Pala, L., Monami, M., & Mannucci, E. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0920-2 · Cited by 6
Clinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes
Gandhi, G. Y., & Mooradian, A. D. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00900-3 · Cited by 12
Bevier, W. C., CASTORINO, K. N., AXELROD, C., Haroush, G., Farfan, C. C., Shelton, N., Nelson, K., Spink, L. A., Liu, H., & Kerr, D. E. (2021) · Diabetes Care · doi:10.2337/dc21-1524 · Cited by 6
Modern basal insulin analogs: An incomplete story
Singh, A. K., & Gangopadhyay, K. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.140239 · Cited by 6
Builes-Montaño, C. E., Wandurraga-Sánchez, E. A., Ramírez, Á., & Ordóñez, J. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01471-9 · Cited by 5
Ghosal, S., Sinha, B., & Gangopadhyay, K. K. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s63878 · Cited by 6
Kaku, K., & Eid, M. A. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12348 · Cited by 6
Clinical and cost–effectiveness of insulin degludec: from clinical trials to clinical practice
Evans, M., & McEwan, P. C. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.15.10 · Cited by 5
Problem Based Review: The patient who has taken an overdose of long-acting insulin analogue
Eldred, A. E., Mustafa, O. G., Hunt, K. F., & Whitelaw, B. (2013) · Acute Medicine Journal · doi:10.52964/amja.0312 · Cited by 5
Laureano, F. C. S., Fernández-Ladreda, M. T., Millán, A. I. J., Calzado, C. G., & Ortega, M. D. C. A. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001633 · Cited by 6
Insulin Degludec, a Long-Acting Once-Daily Basal Analogue for Type 1 and Type 2 Diabetes Mellitus
Berard, L., & Macneill, G. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.02.019 · Cited by 6
Nuevas insulinas en la diabetes tipo 1
Mesa, J. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.04.024 · Cited by 7
Weatherall, J., Bloudek, L. M., & Buchs, S. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1251893 · Cited by 6
Kochar, I. S., & Sethi, A. (2018) · International Journal of Pediatric Endocrinology · doi:10.1186/s13633-018-0059-0 · Cited by 6
Agmon, O., Sigawi, T., & Ilan, Y. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100262 · Cited by 6
Thammakosol, K., Jantarapootirat, M., Traiwanatham, S., & Sriphrapradang, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70101 · Cited by 6
Eto, T., Haranaka, M., Kristensen, N. R., Navarria, A., Nishida, T., Ribel‐Madsen, R., Søgaard, S. B., & Halberg, I. B. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14384 · Cited by 6
“Still, rates were lower than those previously reported in trials with deglu-dec in T1D (42.5 – 88.3 episodes per PYE) 19 – 22 .”
InfluentialHamasaki, H., Nakayama, T., Yamaguchi, A., Moriyama, S., Katsuyama, H., Kakei, M., & Yanai, H. (2014) · Journal of Endocrinology and Metabolism · doi:10.4021/jem.v3i6.193 · Cited by 4
“In clinical trials, insulin degludec achieved similar glycemic control to that with insulin glargine in patients with type 1 or 2 diabetes, with a lower risk of noctural hypoglycemia [7, 9, 10, 14].”
BackgroundMethodInfluentialShould we Fear Insulin Therapy in the Treatment of Type 2 Diabetes?
Haslam, D. B. (2014) · The Open Obesity Journal · doi:10.2174/1876823701406010070 · Cited by 4
Advances in Basal Insulin Therapy
Goldman, J. D., & White, J. R. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122516667128 · Cited by 4
“There were comparable rates of hypoglycemia at any time of day in the 2 studies, and the rate of nocturnal hypoglycemia was significantly lower with Deg-100 Flex in BEGIN Flex T1 but comparable in BEGIN Flex T2 (Table 2).(30,31) These trials also showed that as a result of the long duration of action of insulin deglud…”
BackgroundMethodResultInfluentialKesavadev, J., Murthy, L. S., Chaudhury, T., Yalamanchi, S. R., Giri, J., Gupta, S., Phatak, S., Modi, K. D., Chatterjee, S., Manjunath, A., et al. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100184 · Cited by 4
Thalange, N. K. S., Biester, T., & Danne, T. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0641-3 · Cited by 4
Novel and Emerging Insulin Preparations for Type 2 Diabetes
Cheung, K. K. T., & Senior, P. A. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.082 · Cited by 4
New insulin types in type 1 diabetes mellitus
Mesa, J. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2014.04.005 · Cited by 7
Inpatient hyperglycemia management: the opportunities of a new basal insulin
Simioni, N. (2016) · Italian Journal of Medicine · doi:10.4081/itjm.2016.681 · Cited by 4
New Insulins and Insulin Therapy
Bolinder, J., & Danne, T. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.1505 · Cited by 4
A New Basal Insulin Option: The BEGIN Trials in Patients With Type 2 Diabetes
Battise, D. M. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.4.166 · Cited by 4
Shestakova, M. V., Antciferov, M. V., Mayorov, A. Y., Ruyatkina, L. A., Суплотова, Л. А., Dogadin, S. A., Lebedev, N. B., & Alekseeva, Y. G. (2015) · Diabetes Mellitus · doi:10.14341/dm7694 · Cited by 5
Severe Hypoglycemia in Adults With Type 1 Diabetes After Switching to Insulin Degludec
Aktürk, H. K., & Shah, V. N. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817742922 · Cited by 3
“The insulin degludec has been shown improve fasting glucose control and associated with reduced nocturnal and overall hypoglycemia compared to insulin glargine.(2-4) Flexibility in taking insulin and a lower rate of hypoglycemia makes insulin degludec an ideal choice of insulin for patients with type 1 diabetes.”
BackgroundHaluzík, M. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.019 · Cited by 4
Guarnotta, V., Bella, G. D., Pillitteri, G., Ciresi, A., & Giordano, C. S. D. S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00428 · Cited by 3
Júnior, W. S. D. S., Gabbay, M. A. L., Lamounier, R. N., Calliari, L. E., & Bertoluci, M. C. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00949-z · Cited by 4
“In this 26-weeks openlabel, treat-to-target clinical trial, degludec administered in a forced flexible regimen (minimum interval of 8 h and maximum interval of 40 h between doses) was shown to be safe and non-inferior to the use of insulin degludec or glargine U100 given at fixed times [22].”
Methodde Adana, M. S. R., Domínguez, M., Morillas, V., Colomo, N., Mora, M. R. V., Guerrero, M., García‐Escobar, E., Carreira, M., Romero‐Zerbo, S., Linares, F., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110238 · Cited by 3
Insulin degludec – The impact of a new basal insulin on care in type 2 diabetes
Khunti, K., Cos, X., & Rutten, G. E. H. M. (2013) · Primary care diabetes · doi:10.1016/j.pcd.2013.09.003 · Cited by 2
“[35] C.”
BackgroundCharacteristics and practicalities of a new basal insulin
Stockley, S. (2014) · British Journal of Nursing · doi:10.12968/bjon.2014.23.1.16 · Cited by 2
Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus
Keating, G. M. (2013) · Drugs & Therapy Perspectives · doi:10.1007/s40267-013-0073-5 · Cited by 2
“injection-site swelling/urticaria/haematoma) occurred in 1–6 % of insulin degludec recipients and 2–7 % of insulin glargine recipients [11–15, 18], and none were severe [11, 13] or serious [12].”
InfluentialInsulin Therapy in Type 2 Diabetes
Moghissi, E. S. (2013) · US Endocrinology · doi:10.17925/use.2013.09.01.6 · Cited by 2
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Rendell, M. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s132581 · Cited by 3
McCarthy, O. M., Bain, S. C., & Deere, R. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.63 · Cited by 2
“Finally, the peak-less, extended and highly predictable glucose lowering profile of IDeg allows for variation in the once-daily-dosing strategy of up to 8 hours (25,26) which has important social and practical patient appeals (27).”
BackgroundSelf-citationHamasaki, H. (2013) · Journal of Endocrinology and Metabolism · doi:10.4021/jem193w · Cited by 6
Lüdemann, J., Milek, K., Wilhelm, B., Segner, A., & Jaeckel, E. (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-3481-0 · Cited by 2
Ono, Y., Nishida, T., Hyllested-Winge, J. L., Seino, H., & Sasaki, T. (2016) · Diabetology International · doi:10.1007/s13340-016-0267-x · Cited by 2
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec
WANGNOO, S. K., Baruah, M. P., Lodha, S., Sanyal, D., Goyal, R., Sooragonda, B. G., Chandrasekaran, S., & Kumar, G. V. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01707-w · Cited by 2
Farahani, P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.913980 · Cited by 1
“In 26-week, randomized, open-label, parallel-group, trial studies, the efficacy and safety of insulin degludec once daily with varying injection timing day to day in subjects with Type 1 and Type 2 diabetes was evaluated [21,22].”
BackgroundMethodEfficacy without barriers to insulin therapy: lessons from the BEGIN trial programme.
Mithal, A., Kumar, A., Jain, S. M., & Kumar, H. (2014) · PubMed · Cited by 1
Degludec: a long-duration insulin
Alexanderson-Rosas, E. G., Llamas-Moreno, J. F., Castro-Martínez, M. G., Frenk-Barón, P., Romo-Pérez, O. A., & Mena-Madrazo, J. A. (2015) · Medicina Interna de México · Cited by 2
New Pharmacologic Agents for Diabetes Treatment.
Malham, S. B., & Herrick, C. (2016) · Europe PMC (PubMed Central) · Cited by 1
Sellbom, M., & Nilsson, C. (2021) · Practical Diabetes · doi:10.1002/pdi.2327 · Cited by 1
Efficacy, safety and clinical use of newer basal insulins analogs
Neto, A. M., & Ferrari, M. T. M. (2018) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2018.06.00178 · Cited by 2
Globa, E., & Zelinska, N. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-2-24 · Cited by 1
Zelinska, N. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-4-39 · Cited by 1
▼Insulin degludec for diabetes mellitus
(2013) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2013.7.0190 · Cited by 1
Injectable Systems for Long-Lasting Insulin Therapy
Niloy, K. K. (2019) · doi:10.21007/etd.cghs.2019.0479 · Cited by 2
“As a result, patients who are on once daily insulin degludec dosing regimen, in case of missing dose, can take the dose with time intervals of minimum 8 hours to maximum 40 hours without compromising the glycemic control [63, 64].”
BackgroundAmpudia‐Blasco, F. J. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.10.001 · Cited by 2
Cariou, B. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70806-5
Insulin degludec — ein neues Basalinsulin zur Behandlung von Typ-1- und Typ-2-Diabetes
Gallwitz, B., & Haak, T. (2013) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-013-2186-0 · Cited by 1
Инсулин деглудек - новый аналог инсулина сверхдлительного действия
Russian Federation (2014)
Understanding the safety of the new ultra long acting basal insulin.
Ramachandran, A., Gupta, V., Kesavadev, J., & Kalra, S. (2014) · PubMed
Clinical Use of New Insulins and New Insulin Delivery Systems
Lim, T., & Ko, S. (2015) · Journal of Korean Diabetes · doi:10.4093/jkd.2015.16.4.242
Flexible Injektionszeiten sind möglich
Jaursch-Hancke, C. (2013) · Info Diabetologie · doi:10.1007/s15034-013-0285-8
Kalashnikova, M. F., Yazykova, D. R., Likhodey, N. V., Зилов, А. В., Sych, Y. P., Maloletkina, E. S., & Fadeev, V. V. (2016) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2016-44-4-392-405
Hypoglycemia with New Generation Basal Analog Insulins: A Descriptive Critical Review
Thrasher, M. A. J. R. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000576
“Insulin degludec: In their meta-analysis of phase 3 trials of IDeg versus Gla-100, Vora et al. reported that the two agents had similar efficacy in terms of reduction of A1C in T1DM patients [45].”
BackgroundInfluentialMöglichkeiten und Grenzen der aktuellen Insulintherapie
Forst, T. M. (2017) · Info Diabetologie · doi:10.1007/s15034-017-0976-7
Medina, A. G. M., Olivares, C., Salinas, C., Rosselli, C., Barón, R. A., Ocampo, D., Tovar, A. P., Rincón, O., Villegas, I., & Fortich, Á. (2017) · Alad · doi:10.24875/alad.17000236
Möglichkeiten und Grenzen der aktuellen Insulintherapie: Diabetes mellitus
Forst, T. M. (2018) · CME · doi:10.1007/s11298-018-6417-7
The role of emerging insulin and regimens in overcoming insulin treatment resistance
Barag, S., Meshefedjian, T., & Diep, K. (2017) · Integrative Obesity and Diabetes · doi:10.15761/iod.1000194
“Insulin degludec is an ultra long-acting insulin analog, which possesses a glutamic acid spacer linking a 16-carbon fatty di-acid chain in the place of the threonine at the B30 position in human insulin [1].”
BackgroundDiabetes mellitus Typ 1 – neue Entwicklungen in der intensivierten Insulintherapie
Gerber, P. A., Zimmermann, D., & Spinas, G. A. (2013) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2013.01525
Metadata
- Authors
- Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Baylor University Medical Center (US)
- University of Miami (US)
- Stavanger University Hospital (NO)
- Central Clinical Hospital (PL)
- Royal Surrey County Hospital (GB)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S (J.L., S.C.T.), DK-2860 Søborg, Denmark
- Swansea University (GB)
- Corresponding author
- Mathieu, Chantal
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-03-01
- Volume
- 98
- Issue
- 3
- Pages
- 1154-1162
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3612802
- OpenAlex
- W2044617125
- Semantic Scholar
- 5d22f297ac5f19579d628d305c28db5f36165eaf
- Cited by
- 219
- References
- 25
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 11 · 2018: 19 · 2017: 27 · 2016: 24 · 2015: 27 · 2014: 29 · 2013: 24
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Cardiff University
- European Foundation for the Study of Diabetes
- Novo Nordisk
- Servier
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- insulin degludec, insulin glargine, type 1 diabetes, basal insulin, flexible dosing, injection timing, HbA1c, fasting blood glucose, hypoglycemia, nocturnal hypoglycemia, insulin adherence, basal insulin therapy, non-inferiority, glycemic control, long-acting insulin analogues
- MeSH terms
- Insulin Glargine, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Self Administration, Treatment Outcome, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.